During the past decade, Mammazentrum Hamburg am Krankenhaus Jerusalem conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mammazentrum Hamburg am Krankenhaus Jerusalem" #1 sponsor was "AGO Research GmbH" with 2 trials, followed by "Cankado GmbH" with 1 trials sponsored, "Charite University, Berlin, Germany" with 1 trials sponsored, "Dompé Farmaceutici S.p.A" with 1 trials sponsored and "Fondazione Michelangelo" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mammazentrum Hamburg am Krankenhaus Jerusalem" #1 collaborator was "Hoffmann-La Roche" with 2 trials as a collaborator, "AGO Study Group" with 1 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "Belgian Gynaecological Oncology Group" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Mammazentrum Hamburg am Krankenhaus Jerusalem" are "Recurrent Ovarian Carcinoma" (3 trials), "Breast Cancer" (2 trials), "Breast Neoplasms" (1 trials), "Early Breast Cancer" (1 trials) and "Epithelial Ovarian Cancer" (1 trials). Many other conditions were trialed in "Mammazentrum Hamburg am Krankenhaus Jerusalem" in a lesser frequency.

Most popular intervention types in "Mammazentrum Hamburg am Krankenhaus Jerusalem" are "Drug" (7 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (4 trials), "Atezolizumab" (2 trials), "Bevacizumab" (2 trials), "Carboplatin" (2 trials) and "Gemcitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Mammazentrum Hamburg am Krankenhaus Jerusalem" are 6 trials for "Female" genders and 3 trials for "All" genders.

Currently, there are NaN active trials in "Mammazentrum Hamburg am Krankenhaus Jerusalem". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Mammazentrum Hamburg am Krankenhaus Jerusalem, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Mammazentrum Hamburg am Krankenhaus Jerusalem, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".